Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Clovis

IBM Watson makes its clinical decision support debut

Supercomputer-powered tool could be a breakthrough in evidence-based medicine

- PMLiVE

Succinct forms market access partnership with Royal Marsden

Agency aims is to tackle non-financial issues relating to new medicines

Bristol-Myers Squibb (BMS) building

BMS Q4 results see earnings increase despite fall in sales

Cost-cutting measures at pharma company help overcome patent losses

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

- PMLiVE

BMS hires Roche’s Mike Burgess to lead drug discovery

Was previously interim head of research and early development at Swiss pharma company

- PMLiVE

Janssen’s Zytiga approved for earlier use in Europe

Prostate cancer drug now licensed for use before chemotherapy

- PMLiVE

New EC anti-smoking plans include ban on flavoured tobacco

Pictorial health warnings on cigarettes and regulation for e-cigarettes also proposed

- PMLiVE

Boehringer takes leukaemia drug volasertib into phase III

Shows positive results in a difficult-to-treat patient population

- PMLiVE

ASH meeting hears of progress with myelofibrosis drugs

New studies suggest momentum is for use of Janus kinase (JAK) inhibitors

- PMLiVE

Eliquis meets targets as long-term VTE therapy

Pfizer and BMS report positive phase III data for the Factor Xa inhibitor

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

Pfizer reports strong data with new breast cancer candidate

Phase II results suggest progression-free survival benefits for PD-0332991

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links